Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Valeant Pharmaceuticals divests Argentina operations
Michael Pearson, chairman and CEO of Valeant, said: “One of our strategic initiatives for 2008 is to divest certain regions and simplify our operations. The sale of our
Michael Pearson, chairman and CEO of Valeant, said: “One of our strategic initiatives for 2008 is to divest certain regions and simplify our operations. The sale of our
Barr filed its abbreviated new drug application (ANDA) containing a paragraph IV certification for a generic Prevacid SoluTab product with the FDA in November 2007. Following receipt of
The three year agreement, with research and other support up to $9.5 million, establishes a university team to help identify promising areas of mutual interest and facilitate project
Total sleep time was increased in the Ambien CR group throughout the study. At week eight, patients reporting sleeping an average of 101 minutes more than baseline compared
The primary objective of the double blind, placebo controlled, crossover trial is to assess the efficacy of two different dose strengths of AZD3480 in adult subjects diagnosed with
As previously announced, the purchase price was $2.4 million, part paid on closing and part subject to achievement of certain milestones. In order to partially fund the acquisition,
Dr McCormack has more than 20 years experience in medical technologies, from fundamental research to product development. He was previously a partner of Global Life Science Ventures (GLSV)
This new sponsored research will focus on the development of a new novel class of compounds that inhibit glycolysis, the metabolic pathway essential to the survival of many
With this acquisition, Miltenyi Biotec strengthens the portfolio in the area of sample preparation. The additional expertise of Medic Tools enables Miltenyi Biotec to further engage in development
Mylan launched its Omeprazole products on August 4, 2003, despite the patent infringement litigation, which at the time was unprecedented in the generic pharmaceutical industry. Robert Coury, vice